Genmab’s October Phase 3 Run Reprices the Pipeline as Shares Double
Genmab shares doubled in three months after positive Phase 3 readouts for Rina-S, epcoritamab and petosemtamab reshaped investor expectations for its oncology pipeline.
Genmab’s shares have doubled over roughly three months after the Danish biotech delivered three positive Phase 3 oncology readouts in October. The move reflects more than a single headline: investors are repricing a pipeline that now has late-stage evidence across ovarian cancer, lymphoma and head-and-neck cancer.
CNBC reported that Genmab shares had doubled in three months and rose 48% in the week following the company’s late-October disclosures. The stock’s reaction was especially sharp after data for petosemtamab, Genmab’s investigational head-and-neck cancer treatment, produced a one-day jump of about 29%.
Three Phase 3 wins in one month
1. Rina-S in platinum-resistant ovarian cancer
On October 23, Genmab reported positive topline results from the Phase 3 RAINFOL-02 trial of rinatabart sesutecan, known as Rina-S. The trial met its primary progression-free-survival endpoint and its key overall-survival endpoint against investigator’s-choice chemotherapy.
In the intent-to-treat population, Genmab reported a 71% reduction in the risk of disease progression or death and a 57% reduction in the risk of death. The company said the safety profile was consistent with the known profile of Rina-S, with no new safety signals identified. The data remain topline results and are scheduled for further presentation and regulatory discussions.
2. Epcoritamab in newly diagnosed diffuse large B-cell lymphoma
On October 5, Genmab and AbbVie announced positive results from the Phase 3 EPCORE DLBCL-2 trial. Fixed-duration epcoritamab, combined with standard R-CHOP chemotherapy, produced a statistically significant and clinically meaningful improvement in progression-free survival compared with R-CHOP alone in newly diagnosed patients with diffuse large B-cell lymphoma and an International Prognostic Index score of 2 to 5.
Genmab and AbbVie said the result was the first Phase 3 study of a bispecific-antibody combination to demonstrate a statistically significant and clinically meaningful progression-free-survival improvement in this frontline DLBCL population. The companies said they would engage regulators on next steps.
3. Petosemtamab plus pembrolizumab in head-and-neck cancer
On October 28, Genmab announced positive first-interim results from the Phase 3 LiGeR-HN1 trial. Petosemtamab combined with pembrolizumab met both primary endpoints in first-line, PD-L1-positive recurrent or metastatic head-and-neck squamous-cell carcinoma.
The combination reduced the risk of death by 50% versus pembrolizumab alone and produced a more than threefold improvement in the odds of an objective response. Genmab reported an overall-survival hazard ratio of 0.50 and an objective-response odds ratio of 3.17. The company said no new safety signals were identified and that full results would be submitted for presentation at a future medical meeting.
Why the market response has been so large
The October results broadened the investment case across three different cancer settings and showed that Genmab’s newer programs can generate meaningful late-stage efficacy signals. They also support the company’s strategy of retaining greater ownership of medicines rather than relying primarily on royalty economics from partnered products.
That strategy creates more upside if the programs are approved and commercialized successfully, but it also increases Genmab’s exposure to development costs, regulatory decisions, launch execution and competitive pressure. A successful Phase 3 readout is not the same as an approval, and neither approval nor a strong stock reaction guarantees commercial success.
What investors should watch next
- Regulatory engagement: Genmab and its partners must determine filing and submission paths for the October trial results.
- Full datasets: The headline topline results need to be evaluated alongside follow-up duration, subgroup consistency and complete safety data.
- Commercial execution: Investors will need to assess pricing, eligible patient populations, competition and manufacturing requirements.
- Portfolio concentration: The rally raises expectations for Genmab’s newer assets, increasing the market’s sensitivity to future readouts.
Bottom line: Genmab’s share-price doubling is a market response to an unusually concentrated run of positive oncology data. The three October Phase 3 wins materially strengthen the company’s pipeline narrative, but the next valuation test will be whether those results translate into regulatory approvals, durable clinical benefit and profitable commercial launches.
Sources
- Genmab: RAINFOL-02 Phase 3 results for Rina-S, October 23, 2026
- Genmab/AbbVie: EPCORE DLBCL-2 Phase 3 results, October 5, 2026
- Genmab: LiGeR-HN1 Phase 3 results for petosemtamab, October 28, 2026
- CNBC: Genmab’s shares double after cancer-drug trial wins, November 3, 2026
Informational content only. This article is not financial advice, medical advice or an investment recommendation. Clinical-trial results are preliminary or topline where stated and do not guarantee regulatory approval or treatment benefit. Review the applicable company disclosures and conduct your own research.